These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7031212)

  • 1. Lack of stimulation of isohemagglutinin antibodies by immunization with group B streptococcal (type III) vaccine.
    Webb BJ; Kasper DL; Baker CJ
    J Pediatr; 1981 Dec; 99(6):918-20. PubMed ID: 7031212
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of bacterial carbohydrate-specific cold agglutinin antibody production with immunization by group C, group B type III, and Streptococcus pneumoniae type XIV streptococcal vaccines.
    Colling RG; Pearson TC; Brown JC
    Infect Immun; 1983 Jul; 41(1):205-13. PubMed ID: 6345390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to group B streptococcus type III and AB blood group antigens induced by pneumococcal vaccine.
    Boyer KM; Theeravuthichai J; Vogel LC; Orlina A; Gotoff SP
    J Pediatr; 1981 Mar; 98(3):374-8. PubMed ID: 7009817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens.
    Baker CJ; Kasper DL; Edwards MS; Schiffman G
    N Engl J Med; 1980 Jul; 303(4):173-8. PubMed ID: 6155612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reformulated Pneumovax available.
    Krakowshi FM; Santopolo AC
    Am Fam Physician; 1982 Jun; 25(6):50. PubMed ID: 7081010
    [No Abstract]   [Full Text] [Related]  

  • 6. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
    Baker CJ; Rench MA; Edwards MS; Carpenter RJ; Hays BM; Kasper DL
    N Engl J Med; 1988 Nov; 319(18):1180-5. PubMed ID: 3050524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgA, IgG and IgM anti-blood group A antibodies induced by pneumococcal vaccine.
    Koskela P; Nurmi T; Häiva VM
    Vaccine; 1988 Jun; 6(3):221-2. PubMed ID: 3420973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection.
    Baker CJ; Rench MA; Kasper DL
    N Engl J Med; 1990 Jun; 322(26):1857-60. PubMed ID: 2190087
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccine prevention of group B streptococcal disease.
    Baker CJ
    Pediatr Ann; 1993 Dec; 22(12):711-4. PubMed ID: 8139871
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.
    Robbins JB; Austrian R; Lee CJ; Rastogi SC; Schiffman G; Henrichsen J; Mäkelä PH; Broome CV; Facklam RR; Tiesjema RH
    J Infect Dis; 1983 Dec; 148(6):1136-59. PubMed ID: 6361173
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurement of human antibodies to type III group B Streptococcus.
    Kasper DL; Wessels MR; Guttormsen HK; Paoletti LC; Edwards MS; Baker CJ
    Infect Immun; 1999 Aug; 67(8):4303-5. PubMed ID: 10447392
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunodeterminant specificity of human immunity to type III group B streptococcus.
    Kasper DL; Baker CJ; Baltimore RS; Crabb JH; Schiffman G; Jennings HJ
    J Exp Med; 1979 Feb; 149(2):327-39. PubMed ID: 84042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection.
    Davies JK; Paoletti LC; McDuffie RS; Madoff LC; Lee S; Eskens J; Gibbs RS
    Am J Obstet Gynecol; 1999 Oct; 181(4):803-8. PubMed ID: 10521733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The soluble antigens of GBS as human vaccines.
    Swenson RM; Eisenstein TK; Shockman GD
    Antibiot Chemother (1971); 1985; 35():291-5. PubMed ID: 3901905
    [No Abstract]   [Full Text] [Related]  

  • 17. Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
    Fischer GW; Lowell GH; Crumrine MH; Bass JW
    J Exp Med; 1978 Sep; 148(3):776-86. PubMed ID: 29937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood group antibodies induced by pneumococcal vaccine.
    Potter EV
    J Pediatr; 1982 May; 100(5):836-7. PubMed ID: 7069555
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoprecipitation and opsonic cross-reaction between type-14 pneumococcus and group-B streptococcus type III.
    Fischer GW; Lowell GH; Crumrine MH; Wilson SR
    Lancet; 1979 Jan; 1(8107):75-7. PubMed ID: 84130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides.
    Robbins JB; Schneerson R
    Bull Eur Physiopathol Respir; 1983; 19(2):215-26. PubMed ID: 6347282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.